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ABSTRACT
Patients with multiple sclerosis (MS) may be at an increased risk of fracture owing to a greater risk of falling and decreased bone mineral
density when compared with the general population. This study was designed to estimate the relative and absolute risk of fracture in
patients with MS. We conducted a population-based cohort study using data from the UK General Practice Research Database linked to
the National Hospital Registry (1997–2008). Incident MS patients (n¼5565) were matched 1:6 by year of birth, sex, and practice with
patients without MS (controls). Cox proportional-hazards models were used to derive adjusted hazard ratios (HRs) for fracture associated
with MS. Time-dependent adjustments were made for age, comorbidity, and drug use. Absolute 5- and 10-year risks of fracture were
estimatedforMSpatientsasafunctionofage.Comparedwithcontrols,MSpatientshadanalmostthreefoldincreasedriskofhipfracture
[HR¼2.79, 95%confidence interval (CI)1.83–4.26] and arisk ofosteoporotic fracture that wasincreased 1.4-fold (HR¼1.35, 95%CI 1.13–
1.62). Risk was greater in patients who had been prescribed oral/intravenous glucocorticoids (GCs; HR¼1.85, 95% CI 1.14–2.98)
or antidepressants (HR¼1.79, 95% CI 1.37–2.35) in the previous 6 months. Absolute fracture risks were low in younger MS patients
but became substantial when patients were older than 60 years of age. It is concluded that MS is associated with an increased
risk of fracture. Fracture risk assessment may be indicated in patients with MS, especially those prescribed GCs or antidepressants.
 2011 American Society for Bone and Mineral Research.
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Introduction
M
ultiple sclerosis (MS) is a neurodegenerative disease
characterizedbythegradualaccumulationoffocalplaques
of demyelination, particularly in the periventricular areas of the
brain. According to the World Health Organization, MS affects
more than 1.3 million people worldwide, including 630,000
Europeans, 520,000 Americans, and 66,000 Eastern Mediterra-
nean patients.
(1)
Patients with MS may be at risk of fracture
(2) owing to an
increased risk of falling
(3–5) and low bone mineral density
(BMD).
(6–10) An increased risk of falling may result from
imbalance, disability, or spasticity.
(3,5,11) Osteoporosis occurs
more frequently among patients with MS, probably as a result
of immobility,
(7,10) a low level of daily activity,
(6,12) vitamin D
deficiency,
(10) and the use of glucocorticoids (GCs).
(6,7,13)
Furthermore, it has been shown that patients with rheumatoid
arthritis (RA), chronic obstructive pulmonary disease (COPD),
or inflammatory bowel disease whose cumulative exposure to
GCs was greater than 1g (in prednisone equivalents) had a
substantially increased risk of osteoporotic fracture.
(14) MS
patients who suffer from a relapse are often prescribed oral
or intravenous methylprednisolone (MPH) with a dosage that
corresponds to 1.5 to 3.3g of prednisone equivalents. A recent
study showed that in patients with RA, the underlying disease
process also may contribute to the fracture risk.
(15) In patients
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2271with MS, there may be a similar association between disease
activityandriskoffracture:Inflammation,whichishighestduring
relapses, may be associated with a reduction in BMD in MS
patients.
(8) However, in MS patients, individual risk profiles for
fracture have not been determined.
The aim of this study was to determine the relative risk of
fracture in patients with MS compared with population-based
controls and to calculate the absolute 5- and 10-year risks of
fracture in MS patients.
Methods
Data source
Information for this study was obtained from the General
Practice Research Database (GPRD). The GPRD comprises
prospectively collected computerized medical records for over
10 million patients under the care of general practitioners (GPs)
in the United Kingdom (UK). It has been the source for numerous
epidemiologic studies, and the accuracy and completeness of
these data have been well validated and documented.
(16)
Previous studies of GPRD data have shown a high level of data
validity with respect to the reporting of fractures.
(17) GPRD data
have been linked to the national Hospital Episode Statistics (HES)
inEnglandforapproximately45%ofallpractices.
(18)Inthisstudy,
data were linked from April 1997 until March 2008.
Study population
The case population consisted of all patients aged 18 years or
older with at least one recorded diagnosis of MS during the
period of GPRD or HES data collection. For this study, GPRD data
collection started in 1987 and ended in August 2009 and HES
data collection started in April 1997 and ended in March 2008
(thereby defining the total study period as 1987 to 2009).
Patients with a history of MS before the start of data collection
were excluded, thereby restricting the case population to
incident MS patients. Patients with MS were stratified to
probable and possible cases at baseline (date of first diagno-
sis/index date). A probable case was defined as someone with a
diagnosisofMSintheGPRDandadiagnosisofMSintheHESora
diagnosis of MS either in the GPRD or the HES and at least one
of the following: (1) an MRI within 6 months of the first diagnosis,
(2) two or more subsequent MS diagnoses (GPRD), and/or (3) a
prescription for either corticotropin, glatiramer, interferon b1a or
b1b, or natalizumab at any time during follow-up. All other
patients with a diagnosis of MS in the GPRD or the HES were
considered possible cases. The case definition of MS has been
developed by a senior neurologist (BU) and a senior pharma-
coepidemiologist who has 8 years’ experience with analysis of
GPRD (FdV). We defined patients free of osteoporosis treatment
at baseline as those who had not been prescribed bispho-
sphonates, raloxifene, strontium ranelate, and/or parathyroid
hormone (PTH) before the start of follow-up.
Each MS patient was matched by year of birth, sex, and
practice to six control individuals (patients without a diagnosis of
MS at any time during their period of registration). The index
date of MS diagnosis was the date of the first record of MS after
the start of valid data collection. Control patients were assigned
the same index date as their matched case. Each patient then
was followed from his or her index date to the end of data
collection, the date of transfer of the patient out of the practice
area, or the patient’s death, whichever came first.
Study outcomes
All patients (cases and controls) were followed up for the
occurrence of fractures. The types of fracture were classified
according to the International Classification of Diseases (ICD-10)
categories. These included skull (S02), neck (S12), ribs (S22),
pelvis (S32), shoulder (S42), forearm (S52), hand (S62), hip/femur
(S72), ankle (S82), foot (S92), or unspecified fractures (T02,
T08, T10, T12). A clinical osteoporotic fracture was defined as
a fracture of the radius/ulna, vertebrae, femur, hip, humerus,
pelvis, or ribs.
The total follow-up period was divided into 30-day intervals.
The presence of risk factors was assessed by reviewing the
computerized medical records for any evidence of risk factors
before the start of an interval. Potential confounders that were
determined at baseline included sex, body mass index (BMI),
smoking status, alcohol use, history of falling, and history of
fracture. Potential confounders that were determined for a time-
dependent analysis included age, a history of chronic diseases
(congestive heart failure, RA, cerebrovascular disease,
(19) inflam-
matory bowel disease, dementia, depression, epilepsy, and
COPD
(20)), as well as evidence of fatigue or visual disturbances
6 months before the start of a 30-day interval. A prescription for
orally or intravenously administered GCs,
(14,21) statins,
(22) anti-
arrythmics, antidiabetics, antidepressants,
(23) antipsychotics,
(24)
hypnotics/anxiolytics, asthma medication, anticonvulsants, hor-
mone-replacement therapy, vitamin D, levothyroxine, baclofen,
or opioids (potencies equivalent to tramadol or higher) in the
previous 6 months also were considered as potential con-
founders. The prescription of a medication was used as a proxy
for use of that drug.
In the United Kingdom, exacerbations of MS are treated with a
short course of orally or intravenously administered MPH.
(25)
Prescriptions can be issued by the GP, or the patient may be
referred to an MS clinic for intravenous MPH on 3 consecutive
days. Information on MPH exposure during MS relapses was
retrieved from anonymous free text, as recorded by the GP or by
the consultant neurologist, in a discharge summary or letter to
the GP. We searched all free-text records of each MS patient with
the following search terms: methylpredniso, methyl-predniso,
methyl predniso, solumedrol, solu medrol, solu-medrol, ivmp,
medrone, ivmp, booster, bolus, pulse ther, and steroid pulse.
Records then were made anonymous, and the date of
administration, MPH dose, and route of administration were
noted. Average daily dose and cumulative dose of oral/
intravenous GCs were determined for the 6-month period
before the start of an interval. The average daily dose was
defined as the total dose of GCs (in prednisolone equivalents)
that was prescribed in the previous 6 months divided by the
number of days.
In the analysis to derive absolute risk, additional specific risk
factors were considered, including vertigo, dizziness, imbalance,
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mal symptoms, cognitive dysfunction, vitamin D deficiency, and
proxyindicatorsofincreaseddisability(i.e.,homevisitsbytheGP,
nursing care, and patient receiving residential care/living in a
care home or using a wheelchair or walking aid) 6 months before
the start of an interval. Furthermore, the use of nonsteroidal
anti-inflammatory drugs (NSAIDs), meprobamate, tizanidine,
dantrolene, modafinil, methylphenidate, or amantadine in the
previous 6 months was included in this analysis.
To create a cohort of patients unexposed to osteoporosis
treatment at baseline, medication records of all participants of
the study (MS cases and controls) were searched for prescrip-
tions of bisphosphonates, raloxifene, strontium ranelate, and
PTH.
Statistical analysis
We compared baseline characteristics between cases and
controls using chi-square testing. Two main analyses were
conducted using Cox proportional-hazards models. The first
analysis compared the fracture risk in MS patients with that in
control patients to yield an estimate of the relative risk [as a
hazard ratio (HR)] of fracture in MS. In that analysis, the
calculations were adjusted for all potential confounders that
changed the HR more than 1% in an age/sex-adjusted analysis.
Analyses were stratified to duration of disease, drug use in the
previous 6 months (including daily and cumulative exposure to
GCs), falling 3 months to 1 year before, and a history of fatigue
and the disability proxy indicator in the previous 6 months. In
addition to the full cohort analysis, we calculated HRs in an
osteoporosis-treatment-naive cohort, where we restricted the
analysis to MS patients and controls free of osteoporosis
treatment at baseline.
In the second analysis, we calculated the long-term risk of
osteoporotic and hip fracture using the full cohort. The Cox
model allows calculation of an individual’s probability of fracture
(i.e., survivor function) for each set of patient characteristics. For
the analysis of long-term risk, we fitted the regression model
withthe generalandspecific riskfactors,whichweredetermined
at baseline, using forward selection. All characteristics, except
age, were included as categorical variables in the regression
models. For the variables of age, sex, and each of the risk factors,
we also investigated possible statistical interactions with MS,
althoughnonewasaddedsubsequentlytothemodel.The5-and
10-year risks of osteoporotic and hip fracture then were
estimated, conditional on patient survival. We evaluated risks
for MS patients in different sex and age categories using their
individual risk profiles. In addition, we estimated risks with GC or
antidepressant use, adding the corresponding risk factor to the
model. Various methods were used to test the fitting of the Cox
models, including a test of the proportional-hazards assumption.
We also compared the observed 5-year probability of fracture
(based on the Kaplan-Meier estimate) with the probability
predicted by the Cox model. To assess the internal validity of the
modelfurther, the C-statistic wascalculated, and weperformed a
10-fold cross-validation. We applied the shrinkage factor that
wefound to the b coefficients of the model, and we adjusted the
C-statistic for overestimation.
A sensitivity analysis was conducted to assess the impact of
defining the index date as the first MS diagnosis 1 year after start
of follow-up. In another sensitivity analysis, we excluded all
probable MS patients who were classified as probable based on
their MRI. All data management and statistical analyses were
conducted using SAS Version 9.1/9.2 software (SAS Institute, Inc.,
Cary, NC, USA).
Results
Thestudypopulation included5565patients withMSand33,360
population-based controls. The mean age at index date (first
diagnosis of MS) was 44.8 years, and 70.0% of the MS patients
werefemale.Themeandurationoffollow-upaftertheindexdate
was 5.7 years for the MS patients and 6.0 years for the control
individuals. Before the index date, 32.2% of the MS patients had
been prescribed at least one antidepressant, 10.0% at least one
anticonvulsant, and 13.2% at least one oral/intravenous GC. In
control patients, these proportions were 21.2%, 2.5%, and 6.4%,
respectively.Fractures wererecordedduringfollow-up in394MS
patients (7.1%) and 1742 control individuals (5.2%). Of all MS
patients, 3386 were classified as probable and 2179 as possible
cases at baseline. Further descriptive details of the participants
are given in Table 1.
Table 2 shows that patients with MS had a 1.2-fold increased
risk of any fracture: adjusted HR¼1.23 [95% confidence interval
(CI) 1.09–1.38]. The risk of osteoporotic fracture was increased
1.4-fold (HR¼1.35, 95% CI 1.13–1.62), and the risk of hip fracture
was increased almost 3-fold (HR¼2.79, 95% CI 1.83–4.26). The
risk of vertebral or radius/ulna fracture was not increased. When
we compared probable MS patients with possible MS patients,
we found that the risk of osteoporotic fracture was higher in
probable patients: HR¼1.46 (95% CI 1.19–1.79) in probable and
HR¼1.14 (95% CI 0.84–1.54) in possible MS patients, although
the difference was not significant (p¼.152). There was a
significant different risk of hip fracture between probable MS
patients (HR¼3.75, 95% CI 2.32–6.07) and possible MS patients
(HR¼1.64, 95% CI 0.81–3.32). Because the risks of fracture in
probable patients were comparable with the risks in all MS
patients, we performed the subsequent analyses in the full MS
cohort, thereby increasing the number of patients. The risks in
the osteoporosis-treatment-naive cohort (5494 MS patients,
32,669 controls) were similar to those in all MS patients.
Table 3 shows that the risk of osteoporotic fracture with any
GC use in the previous 6 months was increased (HR¼1.85, 95%
CI 1.14–2.98). The risk was doubled in patients who had recently
been exposed to daily dosages of 7.5mg of prednisolone
equivalents or more compared with control patients (HR¼2.35,
95% CI 1.35–4.12). In addition, we found a similar increase in risk
of osteoporotic fracture when we evaluated exposure to
cumulative doses of 1g or more of prednisolone equivalents
in the previous year (HR¼2.35, 95% CI 1.34-4.10; data not
shown). The fracture risk with recent GC use was higher in
patients who had been prescribed a short course in the previous
year (HR¼2.67, 95% CI 1.26–5.68), the risk being greater with
orally administered GCs (HR¼4.65, 95% CI 1.88–11.51) than with
intravenously administered GCs (HR¼1.39, 95% CI 0.44–4.45;
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antidepressants, the risk of osteoporotic fracture was almost
doubled. This also was apparent for MS patients with a record of
disability in the previous 6 months. For patients with a record of
falling 1 year to 3 months earlier, the HR was 2.23 (95% CI 1.10–
4.52). No association between the duration of disease (from the
first MS diagnosis) and risk of fracture was apparent. In the
osteoporosis-treatment-naive analysis, we found similar risks as
in the full cohort analysis.
Figure 1 displays the 5- and 10-year risks of osteoporotic and
hip fractures (percentages) in MS patients as a function of their
age. In addition, separate curves were added for the use of oral/
intravenous GCs or antidepressants in the previous 6 months.
The distribution of the 5-year fracture risks in MS patients by
sex and age categories is shown in Table 4. For example,
among women aged 70 to 79 years, the median 5-year risk of
osteoporoticfracturewas9.0%.However,therewasconsiderable
variation in the risk of osteoporotic fracture in this age range
Table 1. Baseline Characteristics of MS Patients and Controls
Characteristic Cases (%) (n¼5565) Controls (%) (n¼33,360)
Female 3897 (70.0) 23,365 (70.0)
Age at index date
Mean 44.8 44.7
By category
18–29 670 (12.0) 4018 (12.0)
30–39 1444 (25.9) 8663 (26.0)
40–49 1617 (29.1) 9700 (29.1)
50–59 1066 (19.2) 6391 (19.2)
60þ 768 (13.8) 4588 (13.8)
Mean duration of disease (years) [95% CI] 5.7 [5.5–5.8] 6.0 [6.0–6.1]
Smoking
Never 2135 (38.4) 15,177 (45.5)
a
Current 1543 (27.7) 7173 (21.5)
a
Ex-smoker 815 (14.6) 4287 (12.9)
a
Unknown 1072 (19.3) 6723 (20.2)
BMI
<20 443 (8.0) 1957 (5.9)
a
20–25 1926 (34.6) 11,384 (34.1)
25–30 1318 (23.7) 8803 (26.4)
a
>30 888 (16.0) 5476 (16.4)
Unknown 990 (17.8) 5740 (17.2)
Disease history
Fracture 829 (14.9) 4498 (13.5)
a
Falling 362 (6.5) 995 (3.0)
a
Fatigue 441 (7.9) 1752 (5.3)
a
Asthma 582 (10.5) 3478 (10.4)
COPD 56 (1.0) 310 (0.9)
Congestive heart failure 33 (0.6) 157 (0.5)
Diabetes mellitus 157 (2.8) 854 (2.6)
Rheumatoid arthritis 34 (0.6) 234 (0.7)
Cerebrovascular incident 158 (2.8) 390 (1.2)
a
Epilepsy 132 (2.4) 448 (1.3)
a
History of drug use
Statins 277 (5.0) 1278 (3.8)
a
Antiarrythmics 32 (0.6) 163 (0.5)
Antidiabetics 130 (2.3) 684 (2.1)
Antidepressants 1794 (32.2) 7066 (21.2)
a
Antipsychotics 226 (4.1) 953 (2.9)
a
Anxiolytics/hypnotics 1187 (21.3) 5048 (15.1)
a
Anticonvulsants 558 (10.0) 823 (2.5)
a
Opioids 386 (6.9) 1217 (3.6)
a
Oral/intravenous glucocorticoids 737 (13.2) 2132 (6.4)
a
CI¼confidence interval; BMI¼body mass index; COPD¼chronic obstructive pulmonary disease.
aStatistically significant difference (p<.05) between cases and controls based on chi-square test.
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theriskprofileand22.3% forthe womeninthe 95thpercentileof
the risk profile. The C-statistic was moderate (0.69) for the
prediction of osteoporotic fracture and excellent (0.89) for the
prediction of hip fracture.
Compared with our primary analysis (Table 2), a sensitivity
analysis yielded similar results when we used a lead-in time of 1
year after the start of data collection. Defining the index date as
the first MS diagnosis after 1 year of data collection reduced the
number of MS patients to n¼4339. The fully adjusted HR for any
fracture was 1.22 (95% CI 1.07–1.39); for osteoporotic fracture, it
was 1.40 (95% CI 1.15–1.70); and for hip fracture, the HR was 2.75
(95% CI 1.71–4.41). Exclusion of all probable MS patients who
were classified as probable based on their MRI resulted in
exclusion of 130 patients from the analysis, and the HRs for
osteoporotic and hip fractures did not change substantially:
HR¼1.45 (95% CI 1.18–1.79) for osteoporotic fracture and
HR¼3.72 (95% CI 2.29–6.05) for hip fracture.
Discussion
In this study we found that for patients with MS, the risk of hip
fracture was almost three times higher than for control patients,
andtheriskofosteoporoticfracturewasincreased1.4-fold. InMS
patients who had been treated recently with oral or intravenous
GCs or antidepressants, the risk of osteoporotic fracture was
almost doubled compared with control individuals. Absolute
fracture risks were low in younger MS patients but became
substantial when patients were older than 60 years of age.
Our findings are in line with those of other studies that have
compared BMD in patients with MS with that in healthy
controls,
(6–10) and they support the hypothesis that MS is
associated with an elevated risk of fracture.
(2) Cosman and
colleagues performed a prospective cohort study on BMD in MS
patients and controls. At baseline, the authors examined the
history of fractures and found significantly more fractures in MS
patients than in controls. In addition, BMD in patients with MS
was lower than in age-matched control individuals—almost 1
SD lower inthe spine and 1to 1.6 SD lower inthe femoral neck.
(6)
Formica and colleagues found that total-body bone mineral
content was decreased in patients with MS (Z-score  0.3 0.1
SD).
(7) Weinstock-Guttman and colleagues reported that 80% of
the male MS patients in their study had a reduced BMD at either
the lumbar spine or the femoral neck. More specifically, 43% had
osteopenia ( 2.5<T-score  1), and 37% had osteoporosis
(T-score  2.5).
(8) Among women with MS, 38% had osteopenia
and 44% had osteoporosis. Ozgocmen and colleagues
(10) found
that BMD of the lumbar spine was nearly 1 SD lower in MS
patients than in the healthy reference population.
There are various explanations for the increased risk of hip
fracture in patients with MS. The etiology may be related to
falling or decreased BMD. It has been shown that patients with
MS have an increased risk of falling compared with healthy
patients.
(3–5) Symptoms of MS include muscle weakness, balance
problems, uncoordinated movements, stiffness, numbness,
tingling, blurred vision, fatigue, and dizziness.
(26) Each symptom
could play a role in the etiology of falling. Previous studies have
investigated the role of disability as a risk factor for falling in
Table 2. Risk of Fracture in MS Patients Compared With Control Patients, by Type of Fracture
Full cohort analysis Osteoporosis-treatment-naı ¨ve analysis
Cases (n¼ 5565); Controls (n¼33,360) Cases (n¼5494); Controls (n¼32,669)
Fracture,
n
Rate/1000
person-years
Age-sex-adjusted
HR (95% CI)
Fully adjusted
HR (95% CI)
Fracture,
n
Rate/1000
person-years
Age-sex-adjusted
HR (95% CI)
Fully adjusted
HR (95% CI)
No MS 1742 8.6 1 1 1686 8.5 1 1
MS
Any fracture 394 12.5 1.52 (1.36–1.69) 1.23 (1.09–1.38)
a 381 12.2 1.50 (1.34–1.68) 1.22 (1.09–1.38)
a
Osteoporotic
j 173 5.5 1.73 (1.46–2.04) 1.35 (1.13–1.62)
b 163 5.2 1.68 (1.41–1.99) 1.31 (1.09–1.57)
b
Hip 37 1.2 3.83 (2.58–5.67) 2.79 (1.83–4.26)
c 36 1.2 4.20 (2.80–6.31) 3.05 (1.97–4.73)
g
Vertebral 8 0.3 1.21 (0.57–2.57) 0.94 (0.43–2.02)
d 7 0.2 1.19 (0.53–2.65) 0.93 (0.41–2.13)
h
Radius/ulna 65 2.1 1.43 (1.10–1.88) 1.16 (0.87–1.55)
e 61 2.0 1.37 (1.04–1.81) 1.12 (0.83–1.50)
e
Other 67 2.1 1.65 (1.26–2.16) 1.27 (0.95–1.69)
f 62 2.0 1.55 (1.17–2.04) 1.19 (0.89–1.60)
f
HR¼hazard ratio; CI¼confidence interval.
aAdjusted for (i) and the use of opioids in the previous 6 months, history of cerebrovascular disease, epilepsy.
bAdjusted for (i) and the use of opioids in the previous 6 months, history of cerebrovascular disease, epilepsy, BMI.
cAdjusted for (i) and the use of opioids in the previous 6 months, history of fatigue in the previous 6 months, BMI.
dAdjusted for age, sex, the use of oral/intravenous glucocorticoids, antidepressants, opioids in the previous 6 months, history of fracture at index date.
eAdjusted for (i) and history of epilepsy, history of visual disturbance in the previous 6 months.
fAdjusted for (i) and the use of opioids in the previous 6 months, history of cerebrovascular disease, epilepsy.
gAdjusted for age, sex, the use of oral/intravenous GCs, antidepressants, anticonvulsants, opioids in the previous 6 months, history of falling at index
date, history of fracture at index date, history of smoking, BMI.
hAdjusted for age, sex, the use of oral/intravenous glucocorticoids, antidepressants in the previous 6 months, history of fracture at index date.
iAge, sex, the use of oral/intravenous glucocorticoids, antidepressants, hypnotics/anxiolytics, anticonvulsants in the previous 6 months, history of falling
at index date, history of fracture at index date, history of smoking.
jThe numbers in the subcategories of osteoporotic fracture do not add up precisely because a patient can sustain more than one fracture, and therefore
different types of fractures, on the same date.
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(3) reported the
occurrence of falls in MS patients with an Expanded Disability
Status Score (EDSS) between 3.5 and 6.0. They found that the
odds of falling were doubled for each whole step on the EDSS.
Finlayson and colleagues
(5) evaluated self-reported falls in 1089
patients with MS and found that never or occasional use of a
wheelchair approximately doubled the risk of a fall compared
with the use of a wheelchair all the time. These results suggest
that, on the one hand, disability may increase the risk of falling
and, on the other, that if a patient always uses a wheelchair, that
actually may protect against falling. However, patients who use a
wheelchairhavedecreasedmobilityandconsequentlyareduced
BMD and ultimately increased risk of fracture. Therefore, the
association between disability and risk of fracture is ambiguous.
In our study, we found that for patients with a record of falling
1 year to 3 months before or with a record of our proxy indicator
of disability in the previous 6 months, the risk of osteoporotic
fracture was approximately doubled.
Table 3. Risk of Osteoporotic Fracture in MS Patients Compared With All Control Patients, by History of Drug Use and Disease Indicators
Full cohort analysis Osteoporosis-treatment-naive analysis
Cases (n¼5565); Controls (n¼33,360) Cases (n¼5494); Controls (n¼32,669)
Fracture, n %
Fully adjusted HR
(95% CI)
a Fracture, n %
Fully adjusted HR
(95% CI)
a
No MS 698 2.1 1 668 2.0 1
MS
Osteoporotic fracture 173 3.1 1.35 (1.13–1.62) 163 3.0 1.31 (1.09–1.57)
Duration of disease
<1 year 26 15.0 1.28 (0.86–1.91) 22 13.5 1.13 (0.73–1.73)
1–5 years 82 47.4 1.45 (1.14–1.84) 77 47.2 1.39 (1.09–1.78)
>5 years 65 37.6 1.28 (0.98–1.67) 64 39.3 1.29 (0.99–1.68)
History of drug use in previous 6 months
Antidepressants
Yes 67 38.7 1.79 (1.37–2.35)
b 59 36.2 1.61 (1.21–2.15)
No 106 61.3 1.28 (1.04–1.58) 104 63.8 1.28 (1.04–1.58)
Antipsychotics
Yes 5 2.9 1.75 (0.72–4.28) 4 2.5 1.48 (0.55–4.01)
No 168 97.1 1.35 (1.13–1.61) 159 97.5 1.31 (1.09–1.57)
Hypnotics/anxiolytics
Yes 29 16.8 1.48 (1.00–2.19) 27 16.6 1.47 (0.98–2.20)
No 144 83.2 1.34 (1.11–1.62) 136 83.4 1.29 (1.07–1.57)
Anticonvulsants
Yes 38 22.0 1.69 (1.20–2.39) 35 21.5 1.65 (1.15–2.36)
No 135 78.0 1.33 (1.10–1.61) 128 78.5 1.30 (1.07–1.57)
Oral/intravenous glucocorticoids
No use 155 89.6 1.34 (1.11–1.61) 148 90.8 1.31 (1.09–1.58)
Any use 18 10.4 1.85 (1.14–2.98) 15 9.2 1.64 (0.98–2.77)
By average daily dose (mg prednisolone equivalents)
<7.5mg 5 2.9 1.19 (0.49–2.87) 5 3.1 1.30 (0.54–3.15)
 7.5mg 13 7.5 2.35 (1.35–4.12) 10 6.1 1.89 (1.01–3.57)
History of falling (3 months to 1 year before)
Yes 8 4.6 2.23 (1.10–4.52) 7 4.3 2.05 (0.96–4.35)
No 165 95.4 1.36 (1.13–1.63) 156 95.7 1.32 (1.09–1.58)
History of MS indicators 6 months before
Fatigue
Yes 5 2.9 2.35 (0.97–5.70) 5 3.1 2.41 (0.99–5.86)
No 168 97.1 1.34 (1.12–1.60) 158 96.9 1.29 (1.07–1.56)
Disability proxy
Yes 24 13.9 1.82 (1.19–2.78) 19 11.7 1.53 (0.96–2.45)
No 149 86.1 1.31 (1.08–1.58) 144 88.3 1.29 (1.07–1.56)
HR¼hazard ratio; CI¼confidence interval.
aAdjusted for age, sex, the use of oral/intravenous glucocorticoids, antidepressants, hypnotics/anxiolytics, anticonvulsants, opioids in the previous
6 months, history of falling at index date, history of fracture at index date, history of cerebrovascular disease, epilepsy, history of smoking, BMI.
bStatistically significant difference (p<.05) between MS patients with a history of medication use and MS patients unexposed to the same class of
medication based on Wald test.
2276 Journal of Bone and Mineral Research BAZELIER ET AL.A reduced BMD in MS may be caused by the patient’s
immobility,
(7,10) vitamin D deficiency,
(10) or use of GCs
(6,7,13) or
antidepressants.
(23) Bone loss associated with physical inactivity
can be explained by increased renal calcium losses, decreased
gastrointestinal calcium absorption, secondary hyperparathy-
roidism, and increased bone turnover with depression of bone
formation.
(7) It has been demonstrated that patients with MS
have lower levels of vitamin D than the general population,
(10)
whichalsomaycontributetoareducedBMDinMS.Furthermore,
MS is an inflammatory autoimmune disorder.
(27) The inflamma-
tion, which is highest during relapses, may be associated with
bone loss in MS patients.
(8)
GC-induced osteoporosis involves systemic effects or direct
effects on bone cells leading to induction of apoptosis in
osteoblasts and osteocytes or suppression of their differentia-
tion.
(28,29) In this study we found that patients who were
prescribed oral or intravenous GCs had higher fracture risks and
that this relationship was dose-dependent. In patients who had
been prescribed 7.5mg or more of prednisone equivalents per
day in the previous 6 months, the risk of osteoporotic fracture
was almost doubled compared with control individuals. This
result is in line with earlier studies that have linked GC use with
increased fracture risk.
(13,20,30,31) During relapses, patients with
MS are often prescribed high doses of MPH. We found that in
patientswhohadbeenprescribedshort coursesrecently,therisk
of fracture was increased further. However, we cannot exclude
that the increased risk is due in part to an increased physical
impairment caused by a more active disease resulting in GC
treatment. Another explanation for the increased risk of fracture
might be the greater use of antidepressants in MS patients. The
use of antidepressants has been associated with a fracture risk
that is approximately double that of control individuals.
(32) This
may be caused by use of the antidepressant itself, which could
affect the microarchitecture of bone
(33–35) or could lead to
falls.
(36) The underlying disease also may play a role in the
increased fracture risk.
(37)
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Fig. 1. Five- and 10-year risks of osteoporotic and hip fractures (%) in MS patients in relation to age [306 197mm (600 600 dpi)].
Table 4. Five-Year Risk of Fracture in MS Patients at the 5th,
50th, and 95th Percentiles of Risk Profiles
Osteoporotic fracture Hip fracture
5th 50th 95th 5th 50th 95th
Women
18–49 0.7 1.6 3.8 0.0 0.1 0.3
50–59 2.2 3.4 8.2 0.1 0.3 1.3
60–69 3.4 5.7 13.0 0.4 1.1 3.7
70–79 6.2 9.0 22.3 1.3 3.8 15.3
80þ 9.8 15.8 35.2 6.4 12.1 46.0
Men
18–49 0.5 1.2 3.0 0.0 0.1 0.3
50–59 1.6 2.4 5.7 0.1 0.3 1.1
60–69 2.5 3.7 8.5 0.4 1.0 3.0
70–79 3.7 5.7 18.9 1.1 2.8 12.0
80þ 6.8 12.7 25.5 5.8 8.7 53.5
FRACTURE RISK IN MS PATIENTS Journal of Bone and Mineral Research 2277Our study has many strengths. As far as we know, we are the
first to estimate the risk of fracture in patients with MS compared
with healthy control individuals using a large population-based
cohort and the first to estimate absolute fracture risks in MS
patients. Our source population was representative of the total
UK population, and we had detailed longitudinal information on
drug prescribing and other risk factors for fracture, such as low
BMI and smoking status. The link with HES data allowed us to
validate the diagnosis of MS in two independent disease
registries.
Our study has some limitations, however. The first symptoms
of MS can arise several years before a patient is diagnosed with
MS,andtherefore,thedateofdiagnosisasrecordedontheGPRD
is not entirely reliable. The mean age at index date (first
diagnosis) was 44 years in our study, which is older than the
typical age of MS onset.
(38) However, since the association
between duration of disease (from the first MS diagnosis) and
risk of fracture was very weak, we believe that this would not
change our results substantially. We conducted a sensitivity
analysis using a lead-in period of 1 year after the start of data
collectionandfound similarresults asinouroriginalanalysis.The
reliability of the order of sequence of an MRI and GPRD/HES
diagnosis has not been validated. However, exclusion of
probable MS patients who were classified as probable based
on their MRI did not substantially change our findings. We did
not have routinely collected information on the degree of
disability in MS patients or on the course of their disease (i.e.,
relapsing-remitting or primary or secondary progressive).
Because our source population was representative of the total
UK population and there is no reason to believe that differential
recording of MS would exist according to its classification, we
may assume that approximately 85% to 90% of our MS patients
had relapsing-remitting MS.
(39) Although we constructed a proxy
indicator for disability, we have not been able to account for all
confounding. Furthermore, as already mentioned, the increased
risk of fracture that we found with the exposure to short courses
of GCs may be caused by either the GCs itself or worsening of MS
during these relapses. Data on methylprednisolone use that has
been prescribed during exacerbations may not have been
complete because they were obtained from free-text fields
written by GPs and discharge letters from neurologists. Based
on a large clinical trial in patients with MS,
(40) the average
annualized relapse rate in patients with MS from the general
population was 0.33; we have recorded 2181 treated relapses
within 31,498 person-years, which implies a potential under-
recording rate of 79.0%. This may have led to a nondifferential
misclassification and an underestimation of the 2.7-fold
increased risk of osteoporotic fracture in patients who had
been prescribed a short course of methylprednisolone in the
previous year. The GPRD does not routinely collect vitamin D
levels or BMD measurements. The numbers of vertebral and rib
fractures recorded in this study probably are underreported,
which could have lead to a nondifferential misclassification.
The true associations between MS and risk of any fracture/
osteoporotic fracture therefore may be greater than reported in
our study. We found no association between MS and vertebral
fracture, but a true association may have been masked. The
prescription of drugs had to be used as proxy for exposure
because we could not confirm compliance nor account for the
use of medications available over the counter in the United
Kingdom.
In conclusion, we found that patients with MS had an
increasedriskofosteoporoticfractureandespeciallyhipfracture.
The risk was higher in patients who had recently used oral/
intravenous GCs or antidepressants. Fracture risk assessment
may be indicated in MS patients in particular when they have
recently been prescribed antidepressants or high doses of GCs.
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